DataMeds AI, Inc. (NASDAQ: MEDS) announced on October 20, 2026, that it has received written notification from the Listing Qualifications Staff of Nasdaq confirming the company regained compliance with Nasdaq Listing Rule 5550(b)(1), also known as the Equity Rule.
The company was previously notified of a deficiency on April 13, 2026, due to a stockholders' equity of $(12,447,801) falling below the required minimum of $2,500,000. While Nasdaq previously confirmed the company had regained bid-price compliance on June 9, 2026, the company was granted additional time to address the equity shortfall.
DataMeds stated that compliance with the Equity Rule was achieved based on a Form 8-K filing dated October 13, 2026, which confirmed the company's stockholders' equity exceeded $2,500,000. A subsequent filing on October 16, 2026, provided details on the material events resulting in this increase. The notification of compliance was dated October 19, 2026.
The company noted that if it fails to evidence compliance upon filing its next periodic report, it may be subject to delisting proceedings.
